Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.

The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.

The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.

But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.

Skyscraper-01 stars at AACR's upcoming clinical trial plenary.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.